This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Protective effect of proton pump inhibitor (PPI) against gastrointestinal bleeding in patients receiving oral anticoagulants (oral anticoagulant therapy)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

A meta-analysis was undertaken to estimate the risk of GIB (gastrointestinal bleeding) in patients with OAC (oral anticoagulants) and PPI (proton pump inhibitor) co-therapy:

  • review (10 studies, n=1,970,931) found PPI co-therapy linked to lower odds of total (OR 0.67; 95% CI 0.62-0.74) and major (0.68; 0.63-0.75) GI bleeding
    • for all kinds of OAC except for edoxaban, PPI cotreatment was related to a lower odds of GIB by 24-44%
    • the protective effect of PPI on total GIB was more significant in concurrent antiplatelets or non-steroidal anti-inflammatory drug users and those with high bleeding risks: patients with previous GIB history, HAS-BLED >= 3, or underlying gastrointestinal diseases
  • study authors concluded:
    • in patients who receive OAC, PPI co-therapy is associated with a lower total and major GIB irrespective of ethnic group and OAC type, except for edoxaban
    • PPI co-therapy can be considered particularly in high GIB risk patients

Reference:

  • Ahn HJ, Lee SR, Choi EK, Rhee TM, Kwon S, Oh S, Lip GYH. Protective effect of proton pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022 Aug 3. doi: 10.1111/bcp.15478.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.